drugset / Trial / NCT00520104

Determination of Drug Interactions of Certain Nasal Medications With Intranasal Ketamine

NCT00520104

Phase 1 Unknown 48 enrolled Javelin Pharmaceuticals
RandomizedCrossoverOpen-labelTreatment

Summary

This is an open label, single-center study to determine whether certain nasal medication interact with PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers and in patients with allergic rhinitis.

Timeline

Start
2007-08
Primary completion
2008-02
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 30 mg Intranasal

Indications

No indication recorded.